Immunotherapy for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) combined with standard chemotherapy and radiation for people with advanced head and neck cancer that cannot be removed by surgery. The goal is to see if this combination can improve outcomes by helping the immune system attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with advanced head and neck cancer that cannot be surgically removed.
- Your cancer is in the throat, voice box, mouth, or a specific area of the throat (oropharynx) and has certain stages (like T3-T4 or N2-3).
- You have not had radiation or chemotherapy for head and neck cancer before.
- Your cancer is measurable, meaning it can be seen on imaging or felt by a doctor.
- You are in generally good health, able to do daily activities, and have adequate organ function.
- If you have hepatitis B or C, or HIV, it must be well-controlled and you must be under a specialist's care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.